Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2005
10/26/2005EP1299099B1 Novel use of (r)-(-)-2- 5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts
10/26/2005EP1159455B1 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE
10/26/2005EP1063999B1 Epiallopregnanolone in the treatment of cns disorders
10/26/2005CN1688584A Selective d1/d5 receptor antagonists for the treatment of obesity and CNS disorders
10/26/2005CN1688581A [1, 2, 4]-triazole bicyclic adenosine A2a receptor antagonists
10/26/2005CN1688580A Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
10/26/2005CN1688578A Phosphodiesterase 4 inhibitors
10/26/2005CN1688577A Triazaspiro [5.5] undecane derivatives and drugs comprising the same as the active ingredient
10/26/2005CN1688566A Remedies
10/26/2005CN1688557A Thiazole compounds for treatment of neurodegenerative disorders
10/26/2005CN1688550A 2, 5-dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase MMP12
10/26/2005CN1688548A Process for preparing quinolin antibiotic intermediates
10/26/2005CN1688545A Phosphodiesterase 4 inhibitors, including n-substituted phenylamine and diphenylamine analogs
10/26/2005CN1688544A Fluoro and sulphonylamino containing 3, 6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
10/26/2005CN1688532A Composition based on substituted 1, 3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof
10/26/2005CN1688365A Therapeutic use
10/26/2005CN1688313A Orally dispersible pharmaceutical piribedil composition
10/26/2005CN1688309A Use of 5-HT2 receptor antagonists for the treatment of sleep disorders
10/26/2005CN1688307A 4-aminopiperidine derivatives, processes for their preparation and their use as medicaments
10/26/2005CN1688299A Suppression of cytotoxic protein conformers
10/26/2005CN1688298A Composition, synthesis and therapeutic applications of polyamines
10/26/2005CN1688290A Cannabinoid liquid formulations for mucosal amdinistration
10/26/2005CN1224623C 1-phenysulfonyl-1, 3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use
10/26/2005CN1224614C Indolin-2-one derivatives, preparation and their use as ocytocin receptor ligands
10/26/2005CN1224612C Acetylenic sulfonamide thiol TACE inhibitors
10/26/2005CN1224598C Naphthalene derivatives
10/26/2005CN1224423C Pharmaceutical composition improved in peroral absorbability
10/26/2005CN1224419C Orally administered peptides to ameliorate a therosclerosis
10/26/2005CN1224389C The use of scopolamine salts
10/25/2005US6958416 Valproyltaurinamide derivatives as anticonvulsant amd CNS active agents
10/25/2005US6958396 8-{4-[3-(5-fluoro-1H-indol-3-YL)-Propyl]-Piperazin-1-YL}-2-methyl-4H-Benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site
10/25/2005US6958351 NMDA NR2B antagonists for treatment
10/25/2005US6958349 Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
10/25/2005US6958347 Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists
10/25/2005US6958344 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/25/2005US6958341 Pyrazolopyrimidines as CRF antagonists
10/25/2005US6958338 E.g., 5-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-indole; partial agonists or antagonist at the dopamine D4 receptors; psychoses, schizophrenia, cognition activators; attention deficit disorder; dyskinesia; side effects reduction
10/25/2005US6958336 Anticancer agents; immunosuppressants; antiallergens; antiinflammatory agents
10/25/2005US6958332 Treating an interleukin-12 overproduction-related disorder; treating rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis, or insulin-dependent diabetes mellitus
10/25/2005US6958331 sulfonyl amine derivatives such as {2-(2,2-diphenyl-ethylamino)-5-[4-(4-isopropyl-piperazine-1-carbonyl)-piperidine-1-sulfonyl]-phenyl}-morpholin-4-yl-methanone; pain, inflammation, septic shock
10/25/2005US6958329 1-[3-Methyl-1-(5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]-azepin-7-ylcarbamoyl)-butyl]-cyclohexanecarboxylic acid amide; inhibit processing of amyloid precursor protein (production of A beta -peptide); neurological disorders related to beta -amyloid production: Alzheimer's disease, Down's Syndrome
10/25/2005US6958320 Sel-12 related methods
10/25/2005US6958218 Detecting modulators of brain membrane protein; obtain membrane protein, incubate with ligand and labeled compound, measure level of binding
10/25/2005US6958143 Aftersmoking; converting nicotine to cotinine; discharing in urine
10/25/2005CA2332461C New benzenesulfonamide derivatives, their method of preparation and the pharmaceutical compositions containing them
10/25/2005CA2304974C 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
10/25/2005CA2304657C Treatment of conduct disorder
10/25/2005CA2261725C Piperidine and piperazine derivatives and their use as muscarinic antagonists
10/25/2005CA2147056C Novel delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides
10/20/2005WO2005097814A2 Composition and method for inhibiting platelet aggregation
10/20/2005WO2005097782A1 Piperidine derivative
10/20/2005WO2005097779A1 Diarylamine derivatives as calcium channel blockers
10/20/2005WO2005097183A2 Treatment of diseases
10/20/2005WO2005097166A1 Remedy for diabetic neuropathy comprising gelatin gel as carrier
10/20/2005WO2005097156A1 Remedy for neurodegenerative diseases
10/20/2005WO2005097155A1 Neurite elongation inducing agent
10/20/2005WO2005097117A1 Thiadiazolidinones as gsk-3 inhibitors
10/20/2005WO2005097101A1 Sleep-improving composition
10/20/2005WO2005096717A2 Agent exhibiting hepatoprotective properties
10/20/2005WO2003002094A8 Enhanced pharmacokinetic profile of hydrophobic substances
10/20/2005WO2002097033A3 Antibodies that immunospecifically bind to trail receptors
10/20/2005US20050235367 Regulatory sequences capable of conferring expression of a heterologous DNA sequence in endothelial cells and uses thereof
10/20/2005US20050234248 Method of producing preparations rich in tocotrienol
10/20/2005US20050234247 New effector conjugates, process for their production and their pharmaceutical use
10/20/2005US20050234245 Estrogen receptor modulators
10/20/2005US20050234126 Amide derivatives as inhibitors of the enzymatic activity of renin
10/20/2005US20050234118 Novel aryllimidazole derivatives, preparation and therapeutic used thereof
10/20/2005US20050234116 e.g. 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole; voltage-dependent anion channel, mitochondria porin modulator, apoptosis suppressor, mitochondria function ameliorator; Down syndrome, pigmentary degeneration of retina, alcoholic hepatitis or sideroblastic anemia
10/20/2005US20050234105 Method of treating of demyelinating diseases or conditions
10/20/2005US20050234092 Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease
10/20/2005US20050234090 Modulators of chemokine receptor activity
10/20/2005US20050234088 Urea substituted imidazoquinoline ethers
10/20/2005US20050234082 Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
10/20/2005US20050234081 for inhibiting the enzyme C1s, a protease in the classical pathway of the complement system; and the use of this inhibition to treat or ameliorate acute or chronic disorders in mammals
10/20/2005US20050234079 Novel crystalline form of 5-[4-[[3-methyl-4-oxo-3,4-dihydroquinazolin-2-yl]methoxy] benzyl]thiazolidine-2,4-dione potassium salt
10/20/2005US20050234077 Pyrimidine compounds and their use as modulators of chemokine receptor activity
10/20/2005US20050234063 Therapeutic agent for brain hemorrhage
10/20/2005US20050234062 Such as 2-{4-[(4aS,8aR)-4-(3,4-dimethoxyphenyl)-1-oxo-4a,5,8,8a-tetrahydro-1H-phthalazin-2-yl]-piperidin-1-yl}-2H-acetamide; phosphodiesterase inhibitors; for treatment of respiratory disorders
10/20/2005US20050234061 N-[3-(4-chlorophenyl)-2-(3-pyridyl)-1-methylpropyl]-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide; obesity; antipsychotic agents; synergistic; cannabinoid receptor antagonists
10/20/2005US20050234056 Imidazoquinoline derivatives as adenosine A3 receptor ligands
10/20/2005US20050234051 5-Substituted 2-aryl-4 pyrimidinones
10/20/2005US20050234048 substituted 4,5-dihydro-1H-benzo[b][1,4]-diazepin-2-one; amidation of a substituted monoprotected 1,2-diaminobenzene with an ester, deprotecting, cyclization; chronic neurological disorders, psychosis, schizophrenia, Alzheimer's disease
10/20/2005US20050234041 Substituted 1-benzazepines and derivatives thereof
10/20/2005US20050234039 Substituted lactams as inhibitors of Abeta protein production
10/20/2005US20050234036 3-(2-tetrahydrofuryl-methyl)-2-thioxanthine; neuroinflammatory disorders; pain, cancers, rheumatic arthritis, neurodegenerative diseases
10/20/2005US20050234035 New salts
10/20/2005US20050234029 Compounds
10/20/2005US20050234028 solid dosage form for contraceptives and hormone replacement therapy; very low moisture content to prevent ester hydrolysis; enhanced bioavailability of 17-beta-estradiol
10/20/2005US20050234022 Use of 2-alkoxyphenyl-substituted imidazotriazinones
10/20/2005US20050234017 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
10/20/2005US20050234011 Re-epithelializing pharmaceutical compositions comprising xanthan gum
10/20/2005US20050233969 Analogues of GLP-1
10/20/2005US20050233957 Sodium channel regulators and modulators
10/20/2005US20050233955 Stimulation of nerve cell regeneration
10/20/2005US20050233452 Cell populations which co-express CD49c and CD90
10/20/2005US20050233447 A cell simultaneously expressing albumin protein and a membrane-associated CD14 surface antigen; expresses a mRNA sequence typical of hepatocytes selected from the group consisting of alpha-fetoprotein, carbamyl phosphate synthetase I, coagulation factor II, and coagulation factor VII
10/20/2005US20050233385 Using antibodies on cell surfaces
10/20/2005US20050233371 CNG2B: a novel human cyclic nucleotide-gated ion channel
10/20/2005US20050233359 Isolated nucleic acid molecule encoding a neurotrophic growth factor
10/20/2005US20050233326 Drug screening for binding property or signal transduction between a G protein-coupled receptor and humanin or a salt; Alzheimer*s disease
1 ... 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 ... 1833